DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
+9.69%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$2.75B
AUM Growth
+$2.75B
(-2.3%)
Cap. Flow
-$320M
Cap. Flow
% of AUM
-11.64%
Top 10 Holdings %
Top 10 Hldgs %
32.38%
Holding
133
New
19
Increased
19
Reduced
27
Closed
26
Top Buys
| 1 |
AERI
Aerie Pharmaceuticals, Inc.
AERI
|
$65M |
| 2 |
XENT
Intersect ENT, Inc
XENT
|
$32.4M |
| 3 |
NVRO
NEVRO CORP.
NVRO
|
$29.9M |
| 4 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
$26.9M |
| 5 |
Acadia Healthcare
ACHC
|
$24.1M |
Top Sells
| 1 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
$130M |
| 2 |
Tandem Diabetes Care
TNDM
|
$98.1M |
| 3 |
AET
Aetna Inc
AET
|
$42M |
| 4 |
CVS Health
CVS
|
$35.4M |
| 5 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
$35.2M |
Sector Composition
| 1 | Healthcare | 69.76% |
| 2 | Financials | 1.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $129M | 4.64% | 6,609,894 | – | – |
|
2
Q32 Bio
QTTB
$20.9M
| $119M | 4.28% | 5,227,035 | – | – |
|
|
AERI
3
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $94.8M | 3.4% | 1,540,448 +1,056,393 | +218% | +$65M |
|
4
Viatris
VTRS
$12.3B
| $67.4M | 2.42% | 1,842,111 +100,000 | +6% | +$3.66M |
|
|
PTLA
5
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $65.4M | 2.34% | 2,455,586 +1,008,953 | +70% | +$26.9M |
|
|
DBVT
6
DBV Technologies
DBVT
$264M
| $65.1M | 2.33% | 2,900,000 | – | – |
|
7
AnaptysBio
ANAB
$569M
| $64.6M | 2.31% | 647,466 +84,477 | +15% | +$8.43M |
|
|
XLRN
8
DELISTED
Acceleron Pharma Inc.
XLRN
| $64M | 2.29% | 1,117,651 -9,149 | -0.8% | -$524K |
|
|
ECYT
9
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $62.4M | 2.24% | 3,514,084 +1,189,785 | +51% | +$21.1M |
|
|
XENT
10
DELISTED
Intersect ENT, Inc
XENT
| $61.8M | 2.21% | 2,147,950 +1,127,950 | +111% | +$32.4M |
|
|
MYOK
11
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $59.8M | 2.14% | 917,000 -242,000 | -21% | -$15.8M |
|
12
BioCryst Pharmaceuticals
BCRX
$1.74B
| $52.7M | 1.89% | 6,910,789 +847,293 | +14% | +$6.46M |
|
|
13
Acadia Healthcare
ACHC
$2.12B
| $50.1M | 1.8% | 1,424,571 +683,555 | +92% | +$24.1M |
|
14
argenx
ARGX
$43.6B
| $49.8M | 1.78% | 656,500 +209,471 | +47% | +$15.9M |
|
15
Sarepta Therapeutics
SRPT
$1.78B
| $47.8M | 1.71% | 296,000 | – | – |
|
16
Brookdale Senior Living
BKD
$1.83B
| $46.3M | 1.66% | 4,707,912 +2,402,139 | +104% | +$23.6M |
|
17
Aclaris Therapeutics
ACRS
$209M
| $44.9M | 1.61% | 3,093,416 +347,711 | +13% | +$5.05M |
|
18
Xeris Biopharma Holdings
XERS
$1.26B
| $43.9M | 1.57% | 2,498,666 | – | – |
|
|
BPMC
19
DELISTED
Blueprint Medicines
BPMC
| $41M | 1.47% | 525,000 +50,050 | +11% | +$3.91M |
|
|
MRTX
20
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $39.6M | 1.42% | 840,911 -459,454 | -35% | -$21.6M |
|
21
Glaukos
GKOS
$5.5B
| $37M | 1.32% | 569,356 -184,866 | -25% | -$12M |
|
22
Editas Medicine
EDIT
$231M
| $36.9M | 1.32% | 1,158,841 | – | – |
|
23
Centene
CNC
$14.3B
| $35.5M | 1.27% | 245,000 -79,536 | -25% | -$11.5M |
|
24
eHealth
EHTH
$118M
| $34.7M | 1.24% | 1,227,061 +122,109 | +11% | +$3.45M |
|
25
Universal Health Services
UHS
$11.6B
| $33.5M | 1.2% | 262,000 | – | – |
|